Equities

Medical Developments International Ltd

Medical Developments International Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)0.346
  • Today's Change0.00 / 0.00%
  • Shares traded5.00k
  • 1 Year change-26.27%
  • Beta--
Data delayed at least 15 minutes, as of Jul 24 2024 20:22 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Medical Developments International Limited is an Australia-based company that delivers emergency medical solutions dedicated to improving patient outcomes in both domestic and international markets. The Company operates in two segments: Pain Management and Respiratory. The Pain Management segment is engaged in the supply of analgesia for acute and procedural pain. The Company manufactures inhaled analgesic, Penthrox (the Green Whistle), at manufacturing facilities at Scoresby and Springvale in Victoria, Australia. Penthrox is sold into domestic and international markets through distribution partnerships and direct in-market capability. The Respiratory segment is a supplier of respiratory products including asthma and chronic obstructive pulmonary disease (COPD) space chambers, peak flow meters, portable nebulizers and silicone face masks. Respiratory supplies into Australia, the United States of America, Europe, and Asia through partnerships with distributors.

  • Revenue in AUD (TTM)33.15m
  • Net income in AUD-40.99m
  • Incorporated2003
  • Employees68.00
  • Location
    Medical Developments International Ltd4 Caribbean Drive, ScoresbyMELBOURNE 3179AustraliaAUS
  • Phone+61 39547-1888
  • Fax+61 39547-0262
  • Websitehttps://www.medicaldev.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.